AU2019321654B8 - Compositions and methods for treatment of acute lung injury - Google Patents

Compositions and methods for treatment of acute lung injury

Info

Publication number
AU2019321654B8
AU2019321654B8 AU2019321654A AU2019321654A AU2019321654B8 AU 2019321654 B8 AU2019321654 B8 AU 2019321654B8 AU 2019321654 A AU2019321654 A AU 2019321654A AU 2019321654 A AU2019321654 A AU 2019321654A AU 2019321654 B8 AU2019321654 B8 AU 2019321654B8
Authority
AU
Australia
Prior art keywords
seq
present
pip
absent
lps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019321654A
Other languages
English (en)
Other versions
AU2019321654B1 (en
AU2019321654A1 (en
Inventor
Sheldon I. Feinstein
Aron B. FISHER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of AU2019321654A1 publication Critical patent/AU2019321654A1/en
Publication of AU2019321654B1 publication Critical patent/AU2019321654B1/en
Application granted granted Critical
Publication of AU2019321654B8 publication Critical patent/AU2019321654B8/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019321654A 2018-08-17 2019-08-15 Compositions and methods for treatment of acute lung injury Active AU2019321654B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862719217P 2018-08-17 2018-08-17
US62/719,217 2018-08-17
PCT/US2019/046698 WO2020037146A1 (en) 2018-08-17 2019-08-15 Compositions and methods for treatment of acute lung injury

Publications (3)

Publication Number Publication Date
AU2019321654A1 AU2019321654A1 (en) 2021-03-18
AU2019321654B1 AU2019321654B1 (en) 2025-07-17
AU2019321654B8 true AU2019321654B8 (en) 2025-08-07

Family

ID=69524874

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019321654A Active AU2019321654B8 (en) 2018-08-17 2019-08-15 Compositions and methods for treatment of acute lung injury

Country Status (11)

Country Link
US (2) US12070483B2 (enExample)
EP (1) EP3836953A4 (enExample)
JP (2) JP7483684B2 (enExample)
KR (1) KR20210046698A (enExample)
CN (1) CN112703009B (enExample)
AU (1) AU2019321654B8 (enExample)
BR (1) BR112021002920A2 (enExample)
CA (1) CA3109798A1 (enExample)
IL (1) IL280868B1 (enExample)
MX (1) MX2021001877A (enExample)
WO (1) WO2020037146A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL280868B1 (en) 2018-08-17 2026-05-01 The Trustees Of The Univ Of Pennsylvania Compositions and methods for treating acute lung injury
KR20260034620A (ko) * 2023-05-05 2026-03-11 페록시테크 인코포레이티드. 패혈성 쇼크 치료용 조성물 및 방법
US20240390452A1 (en) * 2023-05-26 2024-11-28 The Trustees Of The University Of Pennsylvania Protective Agent Against Endothelial Dysfunction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861756A (en) * 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
WO2002006301A2 (en) * 2000-06-30 2002-01-24 University Of Cincinnati Peptides with antioxidant and antimicrobial properties

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
ATE173159T1 (de) 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ES2248908T7 (es) 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
PT1251832E (pt) 2000-02-04 2007-01-31 Depomed Inc Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
US20030031711A1 (en) 2001-05-29 2003-02-13 Fara John W. Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
MXPA04010560A (es) * 2002-04-25 2005-08-15 Scripps Research Inst Tratamiento y prevencion de condiciones pulmonares.
EP1764095A1 (en) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel nitrocatechol derivatives having selectin ligand activity
US9012403B2 (en) * 2010-06-18 2015-04-21 Xiberscience Gmbh Peptides as active agents to stabilize biological barriers
US8962570B2 (en) * 2011-05-17 2015-02-24 University of Pittsburgh—of the Commonwealth System of Higher Education Therapeutic use of peptide inhibitors of NADPH oxidase; aerosolization as a delivery mechanism
US11110152B2 (en) * 2016-04-11 2021-09-07 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing lung disease
IL280868B1 (en) 2018-08-17 2026-05-01 The Trustees Of The Univ Of Pennsylvania Compositions and methods for treating acute lung injury

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861756A (en) * 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
WO2002006301A2 (en) * 2000-06-30 2002-01-24 University Of Cincinnati Peptides with antioxidant and antimicrobial properties

Also Published As

Publication number Publication date
AU2019321654B1 (en) 2025-07-17
JP7822065B2 (ja) 2026-03-02
US20210315964A1 (en) 2021-10-14
EP3836953A4 (en) 2022-06-29
BR112021002920A2 (pt) 2021-05-11
JP2021534184A (ja) 2021-12-09
CN112703009B (zh) 2024-06-11
US20250082715A1 (en) 2025-03-13
EP3836953A1 (en) 2021-06-23
US12070483B2 (en) 2024-08-27
MX2021001877A (es) 2021-07-15
AU2019321654A1 (en) 2021-03-18
WO2020037146A1 (en) 2020-02-20
JP2024102207A (ja) 2024-07-30
KR20210046698A (ko) 2021-04-28
IL280868B1 (en) 2026-05-01
IL280868A (en) 2021-04-29
JP7483684B2 (ja) 2024-05-15
CN112703009A (zh) 2021-04-23
CA3109798A1 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
US20250082715A1 (en) Compositions and methods for treatment of acute lung injury
US20230050861A1 (en) Compositions and methods for treating pulmonary edema or lung inflammation
US11400049B2 (en) Pegylated liposomal formulations of apelin for treatment of cardiovascular-related diseases
US8557962B2 (en) Treatment of endothelial dysfunction in diabetic patients
RU2817906C2 (ru) Композиции и способы лечения острого повреждения легких
US12569459B2 (en) Compositions and methods for treating pulmonary edema or lung inflammation
JP7813293B2 (ja) コロナウイルス治療法
US20250235502A1 (en) Cardio-protective effect of vasoconstriction-inhibiting factor (vif)
CN101254299B (zh) 糖尿病患者内皮机能不良的治疗
KR20260034620A (ko) 패혈성 쇼크 치료용 조성물 및 방법
HK40013569B (en) Novel pegylated liposomal formulations of apelin for treatment of cardiovascular-related diseases
HK40013569A (en) Novel pegylated liposomal formulations of apelin for treatment of cardiovascular-related diseases
US20180147268A1 (en) Cystatin c and cystatin 9 to treat inflammation caused by bacteria
Davies et al. HMG Advance Access published November 25, 2005
WO2001003724A1 (en) Therapeutic uses of bpi protein products for inhibiting h+/k+ atpase activity
HK1121938A1 (en) Treatment of endothelial dysfunction in diabetic patients

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 59 , NO 29 , PAGE(S) 4098 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, APPLICATION NO. 2019321654, UNDER INID (43) CORRECT THE PUBLICATION DATE TO READ 20.02.2020

FGA Letters patent sealed or granted (standard patent)